Sorry, you need to enable JavaScript to visit this website.

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06651600 With a Partially Blinded Extension Period to Evaluate the Efficacy and Safety of PF-06651600 and PF-06700841 in Subjects With Active Non-Segmental Vitiligo. A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06651600 With a Partially Blinded Extension Period to Evaluate the Efficacy and Safety of PF-06651600 and PF-06700841 in Subjects With Active Non-Segmental Vitiligo.

Category & Conditions: Skin Diseases and Conditions
Medicine: brepocitinib (PF-06700841) ritlecitinib (PF-06651600)
ClinicalTrials.gov Identifier (NCT): NCT03715829
Protocol ID: B7981019
    Share
PrintDownload
Open Plain Language Summary Result: Click here